Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 12, 2011, Pages 1092-1097

  Ngu, Jing Hieng ^a,b   Gearry, Richard Blair ^a,b   Wright, Andrew Jeffrey ^b   Stedman, Catherine Ann Malcolm ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Autoimmune Liver Disease; Biliary Duct; Cancer Risk; Fibrosis; Inflammation; Mortality

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHOLANGIOGRAPHY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; FEMALE; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGIOPANCREATOGRAPHY, MAGNETIC RESONANCE; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEW ZEALAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82955162705     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.08.027     Document Type: Article

References (37)

1. LaRusso N.F., Shneider B.L., Black D., et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006, 44:746-764.
2. Wiesner R.H., LaRusso N.F. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980, 79:200-206.
3. Karlsen T.H., Schrumpf E., Boberg K.M. Update on primary sclerosing cholangitis. Dig Liver Dis 2010, 42:390-400.
4. Weismüller T.J., Wedemeyer J., Kubicka S., et al. The challenges in primary sclerosing cholangitis: aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008, 48(Suppl 1):S38-S57.
5. Mendes F., Lindor K.D. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol 2010, 7:611-619.
6. Card T.R., Solaymani-Dodaran M., West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008, 48:939-944.
7. Tischendorf J.J., Hecker H., Krüger M., et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102:107-114.
8. Farrant J.M., Hayllar K.M., Wilkinson M.L., et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710-1717.
9. Wiesner R.H., Grambsch P.M., Dickson E.R., et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430-436.
10. Boberg K.M., Aadland E., Jahnsen J., et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
11. Bambha K., Kim W.R., Talwalkar J., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
12. Kingham J.G., Kochar N., Gravenor M.B. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004, 126:1929-1930.
13. Lindkvist B., Benito de Valle M., Gullberg B., et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010, 52:571-577.
14. Kaplan G.G., Laupland K.B., Butzner D., et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007, 102:1042-1049.
15. Fausa O., Schrumpf E., Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991, 11:31-39.
16. Saarinen S., Olerup O., Broomé U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:3195-3199.
17. Ang T.L., Fock K.M., Ng T.M., et al. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 2002, 17:908-913.
18. Takikawa H., Manabe T. Primary sclerosing cholangitis in Japan: analysis of 192 cases. J Gastroenterol 1997, 32:134-137.
19. Takikawa H., Takamori Y., Tanaka A., et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan: presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004, 29:153-159.
20. Broomé U., Olsson R., Lööf L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610-615.
21. Okolicsanyi L., Fabris L., Viaggi S., et al. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables-an Italian multicentre study: the Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996, 8:685-691.
22. Escorsell A., Parés A., Rodés J., et al. Epidemiology of primary sclerosing cholangitis in Spain: Spanish Association for the Study of the Liver. J Hepatol 1994, 21:787-791.
23. Shorbagi A., Bayraktar Y. Primary sclerosing cholangitis: what is the difference between east and west?. World J Gastroenterol 2008, 14:3974-3981.
24. Rabinovitz M., Gavaler J.S., Schade R.R., et al. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease?. A study of sixty-six subjects. Hepatology 1990, 11:7-11.
25. Ngu J.H., Bechly K., Chapman B.A., et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women?. J Gastroenterol Hepatol 2010, 25:1681-1686.
26. Gearry R.B., Richardson A., Frampton C.M., et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006, 12:936-943.
27. Taylor B.V., Pearson J.F., Clarke G., et al. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler 2010, 16:1422-1431.
28. Gibson A., Stamp L.K., Chapman P.T., et al. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatol (Oxford) 2006, 45:624-628.
29. Health expenditure trends in New Zealand 1996-2006 2008, Ministry of Heath, Ministry of Health, Wellington, New Zealand.
30. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6. discussion 16-19.
31. Juran B.D., Atkinson E.J., Schlicht E.M., et al. Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. Liver Int 2010, 31:785-791.
32. Goyette P., Lefebvre C., Ng A., et al. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol 2008, 1:131-138.
33. Karlsen T.H., Franke A., Melum E., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
34. Melum E., Franke A., Schramm C., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011, 43:17-19.
35. Lichtman S.N., Sartor R.B., Keku J., et al. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990, 98:414-423.
36. Kuroe K., Haga Y., Funakoshi O., et al. Pericholangitis in a rabbit colitis model induced by injection of muramyl dipeptide emulsified with a long-chain fatty acid. J Gastroenterol 1996, 31:347-352.
37. Björnsson E., Cederborg A., Akvist A., et al. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2005, 40:1090-1094.